On the call today from management for our opening comments are Steven Roth, Chairman and Chief Executive Officer; and Michael Franco, President and Chief Financial Officer. Thank you, Cathy, and good morning to everyone.
On the call today from management for our opening comments are Steven Roth, Chairman and Chief Executive Officer; and Michael Franco, President and Chief Financial Officer. Thank you, Cathy, and good morning to everyone.
Joining us for today's call are AudioEye's interim CEO, Mr. David Moradi; executive chairman, Dr. Carr Bettis; and CFO, Mr. Before I turn the call over to AudioEye's executive chairman, the company would like to remind all participants that statements made by AudioEye management during the course of this conference call that are not historical facts are considered to be forward-looking statements.
Good afternoon, everyone, and thank you again for joining us in the StoneMor, Inc. conference call to discuss our 2021 first-quarter financial results. With us on the call this afternoon are Joe Redling, president and chief executive officer; and Jeffrey DiGiovanni, senior vice president and chief financial officer.
Workers need time off to stay happy and engaged with their work – denying them this can seriously backfire for businesses.
Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan’s Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG) Management to host conference call today at 2:30 pm CEST (8:30 am ET) May 14, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today reported financial results for the first quarter 2021 and provided a business update. “We’ve had a strong start to 2021 with the acceptance for review of the BLA and J-MAA for efgartigimod in gMG by the regulatory agencies in the U.S. and Japan. The submissions in China and the EU are on track and we are well-positioned for a global launch of our first-in-class FcRn antagonist. We are building an exceptional team with significant launch experience in neurology and rare disease and hope to reach patients this year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “Efgartigimod has the potential to help people living with gMG as well as several other severe autoimmune diseases mediated by IgG autoantibodies. Our team is advancing registrational trials across four indications with plans to start enrollment in two additional efgartigimod indications this year. We are also broadening our reach within autoimmunity with our first-in-class C2 inhibitor, ARGX-117, from which we will have Phase 1 data mid-year. To complement our clinical pipeline, we continue to invest in our discovery capabilities through our Immunology Innovation Program and strategic technology partnerships that position us well to generate long-term value for shareholders. We are closer each day to building an integrated, innovative, global immunology organization with the goal of impacting the lives of patients,” concluded Mr. Van Hauwermeiren. FIRST QUARTER 2021 AND RECENT BUSINESS UPDATE Commercial preparations on-track for global launch of IV efgartigimod for gMG, including regulatory submissions, initial salesforce hires and key stakeholder engagement efforts Biologics License Application (BLA) for IV efgartigimod for treatment of gMG accepted for review by U.S. Food and Drug Administration (FDA) with target action date of December 17, 2021 under Prescription Drug User Fee Act (PDUFA)J-MAA submitted to Japan’s PMDA and accepted for review with anticipated Japan commercial launch in 2022MAA expected to be filed with European Medicines Agency (EMA) in second half of 2021Zai Lab Limited to discuss potential accelerated regulatory pathway for approval in China with National Medical Products Administration (NMPA)Commercial readiness activities on-track, including: Continued build-out of global commercial organization, including hiring of U.S. regional business directors during first quarterLaunched pre-approval access (PAA) program in March 2021 in U.S., Canada and Europe to open availability of efgartigimod to people living with gMG who meet the pre-approval access program criteria Immunology pipeline advancing with five ongoing registrational trials of efgartigimod and initial upcoming data from second potential pipeline-in a product candidate, ARGX-117 Enrollment ongoing in five registrational trials across four indications, including ADAPT-SC (gMG), ADHERE (chronic inflammatory demyelinating polyneuropathy or CIDP), ADVANCE and ADVANCE-SC (primary immune thrombocytopenia or ITP), and ADDRESS (pemphigus) Go-forward decision confirmed in February 2021 in ADHERE trial evaluating subcutaneous (SC) efgartigimod in CIDP based on evaluation of interim safety and efficacy assessments that surpassed pre-defined thresholdEnrollment in trials for fifth and sixth indications to begin in 2021Additional efgartigimod indications to be evaluated as part of collaboration with Zai Lab Limited Data expected mid-year from Phase 1 trial of C2 inhibitor, ARGX-117; Phase 2 dosing plan to be identified for indications, including multifocal motor neuropathy (MMN) Phase 2 trial of MMN on track to start by end of 2021 Combination trials of cusatuzumab remain ongoing for treatment of acute myeloid leukemia (AML) as part of global collaboration and licensing agreement with Cilag GmbH International, an affiliate of Janssen Decision to initiate additional cusatuzumab studies under collaboration will be determined following review of all available data Immunology Innovation Program (IIP) continues to grow pipeline through wholly-owned development, partnered opportunities, asset-centric spinoff companies and the addition of strategic technology capabilities Preclinical work ongoing in early-stage pipeline, including ARGX-118, ARGX-119 and ARGX-12015-20 discovery programs under evaluation at any point in time that have emerged from IIPInitiated collaboration and license agreement with Elektrofi to explore new subcutaneous formulations for current and future pipeline candidates, including efgartigimod Secured exclusivity for FcRn and one additional target Ongoing development of ARGX-112 (LEO Pharma), ARGX-114 (AgomAb), ARGX-115 (ABBV-151, AbbVie) and ARGX-116 (Staten Biotech) by IIP collaboration partners Strong balance sheet and expanded Board of Directors support transition into integrated, global immunology organization Completed public offering of 3,593,750 ordinary shares in February 2021 with gross proceeds of $1.15 billionImplemented transition agreement for Chief Financial Officer Eric Castaldi as part of evolution to commercial-stage company; recruitment efforts ongoing for U.S.-based successorProposed resolutions presented during Annual General Meeting of Shareholders were approved, including: Appointment to Board of Directors of Yvonne Greenstreet, President and Chief Operating Officer of AlnylamRe-appointment of Anthony Rosenberg to Board of DirectorsApproval of new remuneration policy argenx to host virtual R&D Day on July 20, 2021 to share long-term corporate vision, disclose additional potential efgartigimod indications and provide updates across immunology pipeline. FIRST QUARTER 2021 FINANCIAL RESULTS (CONSOLIDATED) Three Months Ended March 31, (in thousands of $ except for shares and EPS) 2021 2020 VarianceRevenue $158,155 $21,139 $137,017Other operating income 9,260 4,672 4,588Total operating income 167,415 25,811 141,604 Research and development expenses (122,328) (104,661) (17,666)Selling, general and administrative expenses (56,253) (27,609) (28,644)Total operating expenses (178,580) (132,270) (46,310)Change in fair value on non-current financial assets 11,152 0 11,152Operating loss $(13) $(106,459) $106,446 Financial income/(expenses) (420) (3,591) 3,171Exchange gain/(losses) (28,817) 22,985 (51,802)Loss before taxes $(29,249) $(87,064) $57,815 Income taxes (11,184) (1,200) (9,984)Loss for the period and total comprehensive loss $(40,433) $(88,264) $47,831 Weighted average number of shares outstanding 49,946,515 42,786,194 Basic and diluted profit/(loss) per share (in $) (0.81) (2.06) Net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2020 and 2019 910,903 (70,318) Cash, cash equivalents and current financial assets at the end of the period 2,907,355 1,430,343 DETAILS OF THE FINANCIAL RESULTS As of January 1, 2021, the Company changed its functional and presentation currency from euro to U.S. dollars, which results in reporting its financial highlights in U.S. dollar as compared to euro in prior periods. Historical financials have been converted at the average exchange rate of the related period. Cash, cash equivalents and current financial assets totaled $2,907.4 million on March 31, 2021, compared to $1,996.5 million on December 31, 2020. The increase in cash, cash equivalents and current financial assets resulted primarily from (i) the closing of a global offering, which resulted in the receipt of $1,092.1 million in net proceeds in February 2021, (ii) the net receipt of a $73.1 million non-creditable, non-refundable development cost-sharing payment in the form of newly issued Zai Lab shares received as part of the strategic collaboration for efgartigimod in Greater China, partially offset by (iii) the payment of $98.0 million related to the purchase of a priority review voucher from Bayer HealthCare Pharmaceuticals and other net cash flows used in operating activities. Total operating income increased by $141.6 million for the three months ended March 31, 2021 to $167.4 million, compared to $25.8 million for the three months ended March 31, 2020. The increase was primarily due to the closing of the strategic collaboration for efgartigimod with Zai Lab, resulting in the recognition of $151.9 million in collaboration revenue. Research and development expenses increased by $17.7 million for the three months ended March 31, 2021 to $122.3 million, compared to $104.7 million for the three months ended March 31, 2020. The increase in the first three months of 2021 resulted primarily from higher external research and development expenses, mainly related to the efgartigimod program in multiple indications and other clinical and preclinical programs. Furthermore, the research and development personnel expenses increased due to a planned increase in headcount and the increased costs of the share-based payment compensation plans related to the grant of stock options. Selling, general and administrative expenses totaled $56.3 million for the three months ended March 31, 2021, compared to $27.6 million for the three months ended March 31, 2020. The increase resulted primarily from higher personnel expenses, including the costs of the share-based payment compensation plans related to the grant of stock options, and consulting fees linked to the preparation of a possible future commercialization of efgartigimod. The increase in fair value on non-current financial assets amounted to $11.2 million for the three months ended March 31, 2021, which is the result of the closing of a Series B financing round of AgomAb Therapeutics, for which the Company maintains a profit share in exchange for granting the license for the use of HGF-mimetic antibodies from the SIMPLE Antibody™ platform. Exchange losses totaled $28.8 million for the three months ended March 31, 2021, compared to an exchange gain of $23.0 million for the three months ended March 31, 2020. As a result of the change in the Company’s functional and presentation currency, the exchange losses for the three months ended March 31, 2021 are reflecting the unfavorable change in euro/U.S. dollar exchange rate, mainly attributable to unrealized exchange rate losses on cash, cash equivalents and current financial asset position in euro. FINANCIAL GUIDANCE Based on current plans to fund anticipated operating expenses and capital expenditures, argenx continues to expect its 2021 cash burn to approximately double from 2020. The increased spend will support the Company’s transition to an integrated immunology company, including the build-out of global commercial infrastructure and drug product inventory ahead of the expected launch of efgartigimod in gMG in the U.S, the advancement of its clinical-stage pipeline, including seven expected global trials of efgartigimod, and the continued investment in its Immunology Innovation Program. EXPECTED 2021 FINANCIAL CALENDAR July 29, 2021: HY 2021 financial results and business updateOctober 28, 2021: Q3 2021 financial results and business update CONFERENCE CALL DETAILSThe first quarter 2021 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 pm CEST/8:30 am ET. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website. Dial-in numbers:Please dial in 15 minutes prior to the live call. Belgium 0800 389 13 France 0805 102 319 Netherlands 0800 949 4506 United Kingdom 0800 279 9489 United States 1 844 808 7140International 1 412 902 0128 About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/ and Twitter at https://twitter.com/argenxglobal. For further information, please contact: Media:Kelsey KirkKKirk@argenx.com Joke Comijn (EU)email@example.com Investors:Beth DelGiaccobdelgiacco@argenx.com Michelle Greenblattmgreenblatt@argenx.com Forward-looking Statements The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” or “should” and include statements argenx makes concerning its statement that the submissions in China and the EU are on track and that it is well-positioned for a global launch of its first-in-class FcRn antagonist, including that BLA for IV efgartigimod for treatment of gMG accepted for review by the U.S. Food and Drug Administration (FDA) in March 2021 with target action date of December 17, 2021 under Prescription Drug User Fee Act (PDUFA), J-MAA submitted to Japan’s PMDA and accepted for review with anticipated Japan commercial launch in 2022, MAA expected to be filed with European Medicines Agency (EMA) in second half of 2021 and Zai Lab Limited to discuss potential accelerated regulatory pathway for approval in China with National Medical Products Administration (NMPA); statements regarding its commercial readiness; its statement that enrollment in trials for fifth and sixth indications to begin in 2021; its statement that data expected mid-year from Phase 1 trial of C2 inhibitor, ARGX-117; Phase 2 dosing plan to be identified for indications including multifocal motor neuropathy (MMN), and Phase 2 trial of MMN on track to start by end of 2021; its expectation that its 2021 cash burn will approximately double from 2020; its hope to reach patients this year; its statements regarding the therapeutic potential of Efgartigimod in patients with gMG as well as several other severe autoimmune diseases mediated by IgG autoantibodies; its plans to start enrollment in two additional efgartigimod indications this year, its expectation to have Phase 1 data mid-year for its C2 inhibitor, ARGX-117, 2021 business and financial outlook and related plans; the therapeutic potential of its product candidates; the intended results of its strategy and argenx’s, and its collaboration partners’, advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts; the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including the effects of the COVID-19 pandemic, argenx’s expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx’s reliance on collaborations with third parties; estimating the commercial potential of argenx’s product candidates; argenx’s ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx’s limited operating history; and argenx’s ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.
Regulated Information Nyrstar NV 2020 Full Year Results 14 May 2021 at 07:00 CEST Nyrstar NV ("Nyrstar" or the “Company”) is today announcing the publication of its financial statements for the twelve months ended 31 December 2020 (“Full Year Results 2020”). The Full Year Results 2020 have been prepared on a discontinuity basis as a result of the decision of the extraordinary shareholders’ meeting of 9 December 2019 to reject the continuation of the Company’s activities. The Company has received from its auditor, and is publishing today, an audit opinion to accompany its Full Year Results 2020. In its audit opinion, the auditor confirms that in its opinion, the annual accounts give a true and fair view of the Company’s net equity and financial position as of 31 December 2020, in accordance with the financial reporting framework applicable in Belgium. The Full Year Results 2020 and the associated reports of the Company’s board of directors have today been published in the reports and presentation section of the Nyrstar website (see https://www.nyrstar.be/en/investors/results-reports-and-presentations/2021). About NyrstarThe Company is incorporated in Belgium and, following completion of the recapitalisation/restructuring has a 2% shareholding in the Nyrstar group. The Company is listed on Euronext Brussels under the symbol NYR. For further information please visit the Nyrstar website: www.nyrstar.be For further information contact: Anthony Simms - Head of External Affairs & Legal M: +41 79 722 2152 firstname.lastname@example.org Attachment FY 2020 Nyrstar results release EN
Geneva, Switzerland, May 14, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its Annual General Meeting will take place on Wednesday 16 June 2021 at 11:00am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva. Due to the global coronavirus (COVID-19) outbreak, the Federal Council has enacted measures to prevent the spread of the coronavirus under the Ordinance on Measures to Combat the Coronavirus (COVID-19) (COVID-19 Ordinance 3). Among other measures, the Federal Council has banned all public and private events in Switzerland and allowed companies to impose on their shareholders the ability to exercise their rights exclusively through voting instructions to the Independent Voting Rights Representative. In accordance with the COVID-19 Ordinance 3, the Board of Directors ordered that all shareholders may exercise their rights at the Annual General Meeting (AGM) exclusively through the Independent Voting Rights Representative, Robert P. Briner, attorney-at-law, B & B Avocats. Shareholders will not be granted access to the meeting room on the day of the meeting. Agenda 1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 20202. Consultative vote on the Compensation Report for the business year 20203. Appropriation of the results4. Discharge of the members of the Board of Directors and of the Executive Management5. Re-elections of the members of the Board of Directors and re-election of the Chairman of the Board of Directors5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors5.2. Re-election of Raymond Hill as member of the Board of Directors5.3. Re-election of Timothy Dyer as member of the Board of Directors5.4. Re-election of Roger Mills as member of the Board of Directors5.5. Re-election of Jake Nunn as member of the Board of Directors5.6. Re-election of Isaac Manke as member of the Board of Directors6. Re-elections of the members of the Compensation Committee6.7. Re-election of Vincent Lawton as member of the Compensation Committee6.8. Re-election of Raymond Hill as member of the Compensation Committee7. Re-election of the Auditors BDO AG8. Re-election of the Independent Voting Rights Representative9. Amendments to the Articles of Association9.9. Creation of an authorized share capital in an amount of CHF 24,636,476 and expiring on 16 June 2023 (article 3b of the Articles of Association)9.10. Increase of the conditional share capital by a total amount of CHF 8,212,159 from CHF 16,424,317 to CHF 24,636,476 (article 3c of the Articles of Association)10. Compensation of the members of the Board of Directors and of the Executive Management10.11. Compensation of the members of the Board of Directors10.12. Compensation of the members of the Executive Management11. MiscellaneousThe full invitation to the AGM 2021 may be found in the General Meetings section of the Company’s website here. About Addex Therapeutics:Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex’s lead product candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in Q2 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q2 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase 2a proof of concept clinical trial for the treatment of epilepsy in Q2 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC, which is focused on development for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange. Press Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55 PR@addextherapeutics.com Mike SinclairPartner, Halsin Partners+44 (0)20 7318 email@example.com James CarbonaraHayden IR+1 (646) 755 firstname.lastname@example.org Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including in respect of the anticipated initiation and progress of clinical trials and preclinical studies, and its future financing activities. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in the Company’s Annual Report on Form 20-F filed with the SEC on March 11, 2021, as well as market conditions and regulatory review. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements, except as required by law.
PRESS RELEASE Regulated Information 14 May 2021, 7:00am, Antwerp (Berchem), Belgium: VGP NV (‘VGP’ or ‘the Group’), a European provider of high-quality logistics and semi-industrial real estate, today published a trading update for the first four months of 2021: Continued strong operating performance €12.5 million signed and renewed lease agreements, bringing total annualized rental income to €196.8 million (+6% year-to-date)A record 1,041,000 m2 under construction representing €64.8 million in additional annual rent once fully built and let (currently 80.1% pre-let)Completed portfolio grown with 58k m2 to 2.50 million m2 which is 99.6% let Expansion of land bank to secure future growth Extended pipeline through 471,000 m2 of new land bought and a further 3.1 million m2 committed subject to permitsTotal land bank acquired and secured has grown to 8.54 million m2 (+11.6% year-to-date) which supports 4.0 million m2 of future lettable area Joint Venture closing anticipated for end of May with expected net cash proceeds of €52 million Advanced discussions with Allianz regarding expansion of first Joint Venture ongoing VGP’s Chief Executive Officer, Jan Van Geet, said: “The year 2021 has started on a strong footing as demand for premium locations remains at elevated levels due to changing consumer behaviour and technological advancements in industry. Year-to-date we have signed €12.5 million of lease agreements and we expect this number to grow in the coming weeks as several signed prelim agreements representing >€10 million are expected to be finalized.” Jan Van Geet continued: "As a result, our predominantly pre-let construction portfolio is topping for the first time 1 million m2, of which over half is situated in Germany (with 215k in VGP Park München) and the other projects well spread across the other European markets. These strong market fundamentals and our resilient delivery put us at pace for another very strong year.” Jan Van Geet concluded: “Our recent inaugural €600 million international green bond offering has allowed us to diversify our funding mix and provides enhanced flexibility for future capital allocation decisions. Whilst maintaining a disciplined and fortress balance sheet, we remain committed to using our resources to drive inclusive and sustainable solutions for the communities we serve as we support our customers in solving their logistics needs or manufacturing real estate requirements. This has enabled us, despite scarcity of permittable land, to continue to make significant investments in the future pipeline, by replenishing and growing our secured land bank with net 900,000 m2 year to date, including several trophy locations which will drive leasing growth in the coming years.” OPERATING HIGHLIGHTS – 4M 2021 Lease operations Signed and renewed rental income of € 12.5 million driven by €11.8 million of new leases (€2.6 million on behalf of the Joint Ventures1) and €0.7 million of renewals (all on behalf of the Joint Ventures). Lease agreements in the amount of € 0.2 million were terminatedAnnualized committed leases at April 2021 (including Joint Ventures at 100%) of €196.8 million (vs €185.2 million at Dec-20) of which €145.9 million related to the Joint VenturesSeveral leasing contracts are in the pipeline and expected to be signed in the coming weeksThe impact of COVID-19 on leasing operations and customer payment behaviour has been minimal with virtually all rent payments received on time Development activities Development of 39 projects under construction totalling 1,041,000 m2 of future lettable area and expected to generate € 64.8 million of new rent when fully built and leased (80.1% pre-let)Geographical split of parks under construction: 53% is located in Germany, 11% Spain, 7% in each Czech Republic and Slovakia, 5% Romania, 4% in each Italy and Netherlands, 3% in each Hungary and Portugal and 1% in AustriaDelivery of 4 projects during the first four months of 2021 of in total 58,000 m2 of lettable area representing € 1.2 million of annualized committed leases; these buildings are 100% letAll construction activities currently run on schedule whilst taking into account the applicable Health and Safety guidance and regulations for all our operations in relation to COVID-19 Land bank During the first four months of 2021 in total 0.47 million m2 of land was acquired representing a development potential of 0.20 million m2A further 3.09 million m2 of land plots are committed, pending permits, and have a development potential of 1.31 million m2 of future lettable area, bringing the total owned and secured land bank to 8.54 million m2 supporting 3.97 million m2 of future lettable areaIn addition 3.83 million m2 of land has been identified and is under exclusive negotiation (representing 1.58 million m2 of future lettable area) Renewable Energy A total solar power generation capacity of 48.8MWp is currently installed or under construction through 45 roof-projects. This is being realised through a €21 million investment to date. In addition, the pipeline identified at the moment equates to an additional power generation capacity of 64 MWp Capital and liquidity position On 31 March 2021, VGP announced the successful issue of a first benchmark international green bond for an aggregate nominal amount of € 600 million, paying a coupon of 1.50 per cent. p.a. and maturing on 8 April 2029. Demand exceeded 2.7 times the volume of the issue. The proceeds from this issuance are being used to fund the majority pre-let development pipeline, the build out of renewable energy assets and the design and development of new green logistics and semi-industrial parksBefore the end of May, we anticipate the eighth closing with VGP European Logistics, the First Joint Venture with Allianz Real Estate. The expected transaction value is €70 million and the expected net cash proceeds amount to €52 million. As the First Joint Venture has reached its expanded investment target, this will be the last closing with the First Joint Venture to include new parks.Advanced discussion with Allianz Real Estate with regards to the expansion of the First Joint Venture are progressing well and expected to be finalized in the coming weeksOn 14 May 2021, the Board of Directors will propose to the Annual Shareholders Meeting to distribute a gross dividend of €3.65 per share corresponding to a total gross dividend amount of €75.1 million, with payment date proposed for 25 May 2021 (to be confirmed by shareholders at the AGM) CONTACT DETAILS FOR INVESTORS AND MEDIA ENQUIRIES Martijn Vlutters (VP – Business Development & Investor Relations)Tel: +32 (0)3 289 1433Petra Vanclova (External Communications)Tel: +42 0 602 262 107Anette NachbarBrunswick GroupTel: +49 152 288 10363 FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements. Such statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. VGP is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release in light of new information, future events or otherwise. The information in this announcement does not constitute an offer to sell or an invitation to buy securities in VGP or an invitation or inducement to engage in any other investment activities. VGP disclaims any liability for statements made or published by third parties and does not undertake any obligation to correct inaccurate data, information, conclusions or opinions published by third parties in relation to this or any other press release issued by VGP. ABOUT VGP VGP is a pan-European developer, manager and owner of high-quality logistics and semi-industrial real estate. VGP operates a fully integrated business model with capabilities and longstanding expertise across the value chain. The company has a development land bank (owned or committed) of 8.54 million m² and the strategic focus is on the development of business parks. Founded in 1998 as a Belgian family-owned real estate developer in the Czech Republic, VGP with a staff of c. 300 employees today owns and operates assets in 11 European countries directly and through several 50:50 joint ventures. As of December 2020, the Gross Asset Value of VGP, including the joint ventures at 100%, amounted to € 3.84 billion and the company had a Net Asset Value (EPRA NAV) of € 1.35 billion. VGP is listed on Euronext Brussels and on the Prague Stock Exchange (ISIN: BE0003878957). For more information, please visit: http://www.vgpparks.eu 1 Joint Ventures means either and each of (i) the First Joint Venture i.e. VGP European Logistics S.à.r.l., the 50:50 joint venture between VGP and Allianz and (ii) the Second Joint Venture i.e. VGP European Logistics 2 S.à.r.l., the 50:50 joint venture between VGP and Allianz, and (iii) the Third Joint Venture i.e. VGP Park München GmbH, the 50:50 joint venture between VGP and Allianz, and (iv) LPM Joint Venture, i.e. LPM Holding B.V., the 50:50 joint venture between VGP and Roozen Landgoederen Beheer Attachment VGP - Trading update - 14 May 2021 (EN)
The Aurora Cultural Centre may not be able to welcome residents into the Church Street School due to Library Square construction, or into their temporary gallery space at Town Hall due to the global pandemic, but curators are ready to bring the arts to you. This Tuesday, May 18, the Aurora Cultural Centre (ACC) will launch a new Arts Talk series, featuring various topics of interest, all tied together by the arts. The first topic will be Arts Education & Mental Health, with subsequent events including Building Arts Programs for our Community on June 18, Addressing Questions on Diversity & Inclusion in the Arts on July 20, and How Are They Doing? Checking In with Artists as We Emerge from the Pandemic on August 17. Arts Education & Children’s Mental Health will feature panellists Tania Marie DeSilva, Clinical Director, Behaviour Matters; Marji Chud, Professor and lead at Young People’s Theatre; Patty Jarvi, Professor and Program Manager for Listen Up!; and in the role of moderator, George Vellathottam of the York Region District School Board. “The effects of arts education on a child’s mental health is vital at the best of times,” says the ACC. “Over the past year, in-school arts programs have either been drastically scaled back or temporarily eliminated due to health and safety guidelines. Join [us] to discover the benefits of arts education to a child’s mental health and sense of community-building, how they view the challenges of the past year, and the way forward as we re-engage children in the arts.” Adds Suzanne Haines, Executive Director of the ACC: “Arts Talk is a new initiative for the Aurora Cultural Centre to engage in conversation with our community on relevant arts topics. Over the next four months, we will welcome expert panelists opening new doors to shared learning in the arts. The first event is on May 18 at 7 p.m. We are inviting the community to join us at the panel discussion to hear about how the arts affect a child’s mental health, what impact this past year in children’s mental health given the pandemic and the change in programming, the benefits of arts education, and opinions on what more we can all do to support arts activities in schools.” To register for the free Arts Talk series, visit auroraculturalcentre.ca/arts-talk. Brock Weir, Local Journalism Initiative Reporter, The Auroran
Zach Plesac came within six outs of ending Cleveland’s 40-year no-hitter drought, keeping the Seattle Mariners hitless into the eighth inning of the Indians’ 4-2 win on Thursday night. The anticipated debuts of Seattle prospects Jarred Kelenic and Logan Gilbert were overshadowed by a masterful pitching performance by Plesac.
Devin Booker made two free throws with 2.4 seconds remaining to give the Phoenix Suns a 118-117 victory over the Portland Trail Blazers on Thursday night. Booker’s winning foul shots were set up when Portland's Robert Covington was fouled and missed both free throws with 4.4 seconds left, giving the Suns one last chance. Booker was fouled by Norman Powell as he went up for a jumper with 2.4 seconds remaining, and Portland's C.J. McCollum missed a 3-point shot at the buzzer to seal Phoenix’s win.
The baseball area round will continue on Friday.
Happy Eid-ul-Fitr 2021 on 14 May 2021: Eid Mubarak Wishes Images, Quotes, Status, Wallpapers, Messages, Photos, GIF Pics.
The next municipal election is less than 18 months away, and preparations are underway for the 2022 vote. This month, Council is poised to endorse a hybrid voting model, one which will once again give eligible Aurora voters a chance to cast their votes for Mayor, Council and Trustee online or in person. But, along with endorsing this model, a reduction in in-person polling stations could be in the offing, a possibility which raised some eyebrows around the General Committee table last week. “Staff are proposing to use internet voting in the advanced voting period, with paper ballot voting being available on specific nights in the advanced period, and as the only option on election day,” said Town Clerk Mike de Rond on his report to Council, noting this will follow much the same pattern as the 2018 municipal election. “While some may have considered the 2018 election to be a transition for the Town going from only a paper ballot in 2014 to full internet voting in 2022, the evidence suggests that the paper ballot is still popular in Aurora with two-thirds of voters choosing that option in 2018. “Should the hybrid method be adopted, the election model will be very close to what residents experienced in 2018. Staff would aim to start the internet voting about 10 days before the election, while simultaneously offering a paper ballot option three to four nights during the week of October 16 – 22, 2022. On election day, staff expect to have between 15 – 20 voting locations in the Town where only a paper ballot will be provided.” Should Council forge ahead with staff’s recommendations, procedures for voting in a situation where the global pandemic is still prevalent are also accounted for. “While staff are hopeful that the current pandemic will not significantly affect the 2022 municipal election, it is important that a plan be in place for the safe casting of votes at polling locations should this pandemic, or any other one, cause the need for safer distance measures than what would normally be in place,” said Mr. De Rond. “Maintaining the secrecy of elections at physical polling locations requires significant space to ensure the voter is making their decision without worrying about being observed, which helps mitigate against physical distancing concerns. The pandemic plan will be focused on lineup control, routing of electors through polling locations and any contingency plans that need to be in place should a lockdown situation be in effect. The foremost concern will be to keep staff at polling locations as well as Town residents safe. Further to this, staff expect internet voting to help mitigate against larger-than-necessary crowds at voting locations.” When the plan came before Council members last week, a number of concerns were addressed. While Councillor John Gallo questioned the fact that staff are recommending a single-source contract to get the job done – in this case, with Dominion Voting Systems – and ensuring systems were in place in the event of a by-election, Councillor Wendy Gaertner focused her questions on ensuring the vote was as accessible as possible. “There is a thought of removing some of the customary polling stations to save a little bit of money,” she said. “You have to keep in mind that the way they are now has really been considered to be accessible…and a lot of people are still going to do in-person voting. I still think it is important to the residents.” Mr. De Rond says analysis hasn’t yet been completed on which polling stations should stay and go, but said that there weren’t “too many lines” in the last municipal election or where there too may complaints. “It’s not that we want to have lines, that’s for certain, but we thought there might be an opportunity to remove some locations,” he said. “We had some that were within a kilometre of each other, sometimes even closer than that. We’re talking between…one in four, probably. Hopefully not as many to cause an impact to the service level.” Brock Weir, Local Journalism Initiative Reporter, The Auroran
DENVER (AP) — Josh Fuentes homered for the second straight game to back seven shutout innings from Chi Chi Gonzalez, and the Colorado Rockies held on for a 13-8 victory over the Cincinnati Reds on Thursday night. Gonzalez (2-1) scattered four hits in his longest outing of the season. He struck out two, walked one and was pulled after 88 pitches. Jonathan India and pinch-hitter Tyler Stephenson homered late for the Reds, who shaved a 10-0 deficit to 10-8 with eight runs in the eighth. Fuentes hit a two-run shot in the first inning off Luis Castillo, then added an RBI single in Colorado’s five-run fourth and another in the sixth to set a career high with four RBIs. Connor Joe had two hits and three RBIs to help the Rockies open the four-game series with a win. Castillo (1-5), the Reds' opening day starter, allowed eight runs and 10 hits in 3 2/3 innings. He is 0-4 in his last six starts. Cincinnati rallied in the eighth against Colorado’s bullpen. Stephenson hit a two-run homer, and five straight singles made it 10-5. India, who started the inning with a single, hit a three-run homer to pull the Reds within two. Colorado scored three times in the bottom of the inning, the last on a solo homer by Garrett Hampson. TRAINER’S ROOM Reds: Manager David Bell said RHP Michael Lorenzen (right shoulder) had positive results from a follow-up MRI and he will be able to start throwing soon in Arizona. ... 1B Joey Votto (thumb) has not resumed baseball activities. Rockies: LHP Kyle Freeland (left shoulder) will have two rehab outings, Saturday and next Thursday, with Triple-A Albuquerque, manager Bud Black said. Freeland will throw 60-70 pitches Saturday. ... Black said INF Brendan Rodgers (hamstring) will start at second base for Albuquerque on Friday. ... SS Trevor Story was given the night off. TWO DOWN Cincinnati lost the game and a couple of players, too. Center fielder Nick Senzel ran into the wall trying to track down Joe’s double in the first inning and left in the third with a bruised left heel. First baseman Mike Moustakas exited in the fifth inning after running into the netting in foul territory in the fourth. He had his finger looked at by the trainer, stayed in for the rest of the inning but was replaced by Alex Blandino in the fifth. BEEN A WHILE Gonzalez's only career complete game came in his second major league start on June 5, 2015, with Texas. UP NEXT Reds LHP Wade Miley (4-2, 2.00 ERA) takes the mound a week after throwing the 17th no-hitter in franchise history. He will face Colorado RHP German Marquez (1-4, 5.49), who has been sharp in two career starts against Cincinnati (2-0, 1.93). ___ More AP MLB: https://apnews.com/hub/MLB and https://twitter.com/AP_Sports Michael Kelly, The Associated Press
Japanese shares led a rebound in Asian markets on Friday, building on the lead from investors on Wall Street snapping up stocks that would benefit most from an economic revival. The rally interrupted a three-day rout for stocks globally, as market jitters over accelerating U.S. inflation were calmed by Federal Reserve officials reiterating that price pressures from the reopening of the economy would prove transitory. "U.S. equities were up, so there is a bit of relief in Asia," said Frank Benzimra, head of Asia equity strategy at Societe Generale in Hong Kong.
The Wyoming congresswoman said the right-wing network "has a particular obligation to make sure people know the election wasn’t stolen."
Omar’s Shoes has been operated by the Khamissa Family for over 51 years. For more than half a century, the popular boutique founded by community-builder Omar Khamissa has been based out of the Aurora Shopping Centre at Yonge and Murray, spurring a second store in East Gwillimbury under the leadership of his son Raz and daughter-in-law Mae. Now, the family is fighting to keep their business in Aurora. This week, the Khamissa family announced they will be closing their flagship location after being unable to resolve issues related to rent relief programs ahead of a new lease. “The financial strain that the COVID pandemic has put us through has been tremendous,” said Raz and Mae in a letter sent out to long-time loyal customers. “Through all of this time, we just kept thinking that we will give it our best to get past this. We have not given up on finding a compromise or maybe another location in Aurora, but only time will tell. We take consolation in knowing that we will continue our business in our location in Newmarket [and] our daughter Saarah will continue our story there. “We would like to thank all of our long-time loyal customers and friends that have supported us over all these years. We have seen three generations of families that have trusted us to look after them. We always felt that if you live in your community they will support you and, in turn, we supported local charities, fundraisers, and sports teams. Aurora has been a wonderful Town to be a part of and we have been proud Aurorans since 1968.” Omar Khamissa emigrated to Canada from South Africa and, before too long, planted roots in his adopted hometown bringing high quality shoes to customers in Aurora and beyond. It was a time when business was sealed with a handshake and word was taken as bond. Although Omar has since passed on, this is a legacy that has been continued by two generations that have followed him. The Khamissas invited The Auroran into their store, which has been closed to the general public due to present health restrictions, last week to share their story – and their sadness that this is a decision they have been forced to make. “We feel after all this time we might be considered a landmark and it is just unfortunate – upsetting, unfortunate, disappointing all at one,” said Raz. “If we find something else, we would love to open back up. If there’s anybody looking, we would love to have them touch base with us.” Raz estimates that over the past 15-or-so months of the global pandemic, they have been closed for over six months. It has been devastating for the business financially, having to continue to pay $25,000 per month for their space. “What has gotten us through this time is curbside. Our customers have been coming to us whether or not they needed the shoes. They have been coming to try and support us to help us get through it. They have been doing it with local restaurants, they have been doing it with local stores, they have been trying to help us independents get through this. When we have been doing curbside fittings, the sentiment has been the same: ‘I hope you can get through this. We love coming to your store. You treat customers so well.’ It gives us great pride to hear that and it kills us to think what is going to happen.” For Mae, the hardest part will be leaving these “phenomenal customers” behind. “They are just incredible people that we have become friends with – that’s what makes us come in every day,” she said. “We have phenomenal staff and the staff have built incredible relationships with customers. “I think of what my father-in-law started here and what this place meant to him,” she said. “He came with nothing in his pocket and started this. In the 80s and 90s people told him, ‘Omar, you have to open up at the mall,’ and he said, ‘I will never leave this plaza. Aurora is my home, you can offer me what you want, but I am never going to leave this place.’ I just remember his words and I remember him telling me, ‘This is my home, these are my people and this is where I am staying. They supported me from Day 1 and I am not leaving.’ “That hurts a hell of a lot because it was his legacy. This is part of not just our family, but all the families over the years that came to us, supported us, and kept on telling us how they preferred coming here because we took the time to give them customer service. Another element that hurts is we have two adults from The Able Network (an Aurora-based organization giving work opportunities for adults with intellectual disabilities) – Adam and Gemma, and Adam has been with us close to 15 years now – and this is where they come to work. This was part of their life. They are looking forward to coming back. This was part of their lives, too, and they are part of our family. It is a chain-reaction for so many, including our staff who have been with us 20 years or so. There have been so many sleepless nights because that is all we talk about and think of.” Added Raz: “We’re not giving up. We’re just thinking, ‘What’s next?’” Omar’s Shoes is planning to have a closing sale as soon as health restrictions allow. Brock Weir, Local Journalism Initiative Reporter, The Auroran
A food magazine raised some eyebrows with its lists of best and worst places for barbecue in the U.S., with no city in Texas on the best list.
Israeli ground forces began launching attacks on Gaza in a widening of hostilities as Israel braced for more internal strife between its Arab and Jewish citizens following Friday prayers. The Israeli military said air and ground forces were firing at the Hamas-run enclave, though it does not appear to mean the start of a ground invasion, with Sky News witnessing troops launching artillery and tank rounds from Israel's side of the border. "I said we would extract a very heavy price from Hamas," Prime Minister Benjamin Netanyahu said in a videotaped statement.
Mayors from across the Greater Toronto and Hamilton Area are calling on the Province for greater “predictability” when it comes to Ontario’s current stay-at-home orders. The current stay-at-home orders are now extended through June 2, but lawmakers began the week seeking more answers from the Ontario government. “Today, Mayors and Chairs from the 11 largest municipal governments across the Greater Toronto and Hamilton Area (GTHA) held their regular weekly meeting to discuss the ongoing response to COVID-19 across the Region,” they said. “The GTHA Mayors and Chairs are asking the Province to provide predictability for the current Provincial stay-at-home order and what is to follow. As the Victoria Day long weekend approaches, people and businesses have begin to ask perfectly reasonable questions as to where things will stand as of that time, so they can make plans of all kinds – business and pleasure. “Accordingly, we think it is important that the Ontario government communicate clearly and as soon as possible whether or not its order will be extended further or modified based on public health advice.” The uncertainty of when the stay-at-home order will be lifted – and, indeed, what will follow – is not the only question being asked of the Provinces. Calls are growing louder from municipal lawmakers – particularly Brampton Mayor Patrick Brown – to allow outdoor sports and athletic activities to re-open, citing lack of evidence that these outdoor pursuits are contributing to the still-high case numbers of COVID-19. The Small Urban GTHA Mayors group consists of the Mayors of Aurora, Bradford West Gwillimbury, the Township of Brock, the City of Burlington, the Towns of East Gwillimbury, Halton Hills, King, Newmarket, Orangeville, the Townships of Scugog and Uxbridge, and the Town of Whitchurch-Stouffville. The group met last week virtually with Prime Minister Justin Trudeau on May 7 to raise concerns on the vaccine rollout, travel bans, the licensing of cannabis facilities and more. “It is only through open dialogue and communication with our Federal partners that municipalities can respond to concerns as a result of changes in legislation impacting our communities,” they said. “We are grateful to the Prime Minister and our Federal Members of Parliament for their continued partnership and support and look forward to continuing to work together in response to the issues raised today.” Brock Weir, Local Journalism Initiative Reporter, The Auroran